Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 22.39M P/E - EPS this Y 5.60% Ern Qtrly Grth -
Income -13.21M Forward P/E -1.43 EPS next Y -39.60% 50D Avg Chg -38.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -48.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -71.00%
Recommedations 1.50 Quick Ratio 1.36 Shares Outstanding 18.96M 52W Low Chg 9.00%
Insider Own 24.33% ROA -81.92% Shares Float 11M Beta 0.71
Inst Own 17.86% ROE -1,098.51% Shares Shorted/Prior 23.05K/24.03K Price 2.61
Gross Margin - Profit Margin - Avg. Volume 258,846 Target Price 8.75
Oper. Margin - Earnings Date Mar 6 Volume 23,507 Change -10.00%
About ProMIS Neurosciences Inc.

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

ProMIS Neurosciences Inc. News
04/30/24 ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies
04/09/24 ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS
04/04/24 ProMIS Neurosciences to Present in Upcoming Investor Conferences in April
04/01/24 ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights
03/11/24 ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio
02/22/24 ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference
01/22/24 ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine
07:00 AM ProMIS Neurosciences Issues Letter to Shareholders
01/03/24 ProMIS Neurosciences, Inc. Announces Leadership Transition
12/20/23 ProMIS Neurosciences Announces Publication on Novel Target for ALS
11/20/23 ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer’s Disease
11/14/23 ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights
06:00 AM ProMIS Neurosciences Closes $20.4 Million Private Placement Financing
09/06/23 ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
08/21/23 ProMIS Neurosciences Announces $20.4 Million Private Placement Financing
08/14/23 ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights
07/17/23 ProMIS Showcases Preclinical Data at the Alzheimer’s Association International Conference 2023 on Computationally-Derived Antibody and Vaccine from Alzheimer’s Pipeline
07/14/23 ProMIS Announces Completion of Continuance
07/10/23 ProMIS Neurosciences to Consolidate Trading on the Nasdaq Exchange
06/30/23 ProMIS Neurosciences Holds Annual Meeting of Shareholders All Resolutions Approved
PMN Chatroom

User Image tradethehalt Posted - 1 week ago

$PMN the price is up 26.24% since we first alerted at 9:30am EDT.

User Image HaltTradeAlert Posted - 1 week ago

$PMN Halt Time: 09:30:16 Issue Symbol: PMN Reason Code: LUDP Last Price: $1.6 Market Cap: $30337760 Volume: 101.0 Relative Volume: 0.02 Shares Float: 18961100 Our members get this alert real time and sent to their phone just like a text. Members also get free real time news catalyst alerts! Go to our website and join our community for free! www.HaltTradeAlert.com

User Image Stock_Titan Posted - 04/30/24

$PMN ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies https://www.stocktitan.net/news/PMN/pro-mis-neurosciences-publishes-study-highlighting-oligomer-x242s4wn37hy.html

User Image Sunny3999 Posted - 04/29/24

$PMN It’s quite lately I am expecting News including a big Pharma partner.

User Image Glopolon Posted - 04/23/24

$PMN Might look for more cash July-August for the Phase 1b. Data from Phase 1a expected released July-August

User Image Glopolon Posted - 04/23/24

$PMN Not one of your typical small Phase 1b, 6 month study followed by 6 month follow up for ARIA detection. 100 patients.

User Image Glopolon Posted - 04/23/24

$PMN They are setting up their Phase 1b trial with other Pharma input, with the hopes of partnering up pending good results. Asset for Alzheimer's treatment - Highly selective for only misfolded, toxic oligomers https://www.promisneurosciences.com/investors/news-events/ir-calendar/detail/8812/bloom-burton-co-healthcare-investor-conference

User Image 7DAYSDIMENSIONS Posted - 04/16/24

$PMN This board is more active becaue PMN was a canadian listed stock before: https://stockhouse.com/companies/bullboard?symbol=pmn

User Image Sunny3999 Posted - 04/10/24

$PMN accumulation is ongoing for sure and soon it will get violent upwards

User Image MrGreenHands Posted - 04/10/24

$PMN in @2.51

User Image Sunny3999 Posted - 04/09/24

$PMN who joined the presentation and how was it? Thanks for info

User Image 7DAYSDIMENSIONS Posted - 04/09/24

$PMN You can watch the presentation this afternoon at 2 PM here: https://ldinv14.sequireevents.com/

User Image 7DAYSDIMENSIONS Posted - 04/09/24

$PMN NEWS OUT https://stockhouse.com/news/press-releases/2024/04/09/promis-neurosciences-publishes-in-the-journal-of-biological-chemistry-on-the

User Image DonCorleone77 Posted - 04/09/24

$PMN ProMIS publishes data on pathogenic proteins as treatment target for ALS ProMIS Neuroscience announced the publication of supportive preclinical data in the Journal of Biological Chemistry in an article titled, "Tryptophan residues in TDP-43 and SOD1 modulate the cross-seeding and toxicity of SOD1." ProMIS is developing antibodies selectively targeting misfolded forms of TDP-43 and SOD1. ALS is a fatal neurodegenerative disease of motor neurons. Toxic aggregates of superoxide dismutase-1 and TAR DNA-binding protein 43 in motor neurons are characteristic of ALS.The study showed that these two proteins interact such that misfolding of TDP-43 leads to misfolding and aggregation of SOD1 in a cell system and promotes motor neuron damage in zebrafish.

User Image Sunny3999 Posted - 04/09/24

$PMN It’s getting hot 🔥 📈https://www.promisneurosciences.com/news-media/press-releases/detail/221/promis-neurosciences-publishes-in-the-journal-of-biological

User Image Stock_Titan Posted - 04/09/24

$PMN ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS https://www.stocktitan.net/news/PMN/pro-mis-neurosciences-publishes-in-the-journal-of-biological-0x5slkyo7ifv.html

User Image 7DAYSDIMENSIONS Posted - 1 month ago

$PMN Last year in July after a presentation the stock sky rocketed unfortunately we all got wiped out with the financing at 1.85. Partnership would be the best way to finish the phase 2 and 3. I'm pretty sure it's already discussed conditional of successful 1a then 1b. Efficacy will be determined in 1b even though it is not supposed to be measured because aducanumab patients had cognitive improvements when on trial. If we have no ARIA and 1b's patients family start begging for the patients to stay on the drug. It will be and orgy of cash. A freaking financial nuke. If not well you lose all your money as usual.

User Image Sunny3999 Posted - 1 month ago

$PMN countdown started 🚀

User Image Sunny3999 Posted - 1 month ago

$PMN expecting parabolic move with next news and steady climbing till July 📈

User Image 7DAYSDIMENSIONS Posted - 1 month ago

$PMN 3 conferences next week with the big boys. No headaches in July and it will be violent. It will be a proof of concept. Efficacy is demonstrated by other biotech co, PMN claimes that their mab is the best in class because of precisely targetting misfolded protein causing AD. If they did that magic trick, it will give a ton of value to their other mabs against ALS, Parkinson and Dementia (Joe Biden).

User Image TerrapinTrade Posted - 1 month ago

@biggercapital never forget $PMN

User Image Bigpun1973 Posted - 1 month ago

$PMN Congrats all of you who are here. I feel this is a sleeping giant✅😀

User Image Bigpun1973 Posted - 1 month ago

$PMN Monday at open👍🔥

User Image Sunny3999 Posted - 1 month ago

$PMN Break out from $2 Level going up to double digits with news

User Image Bigpun1973 Posted - 1 month ago

$PMN Ah Sh👍t it may POP!!

User Image Bigpun1973 Posted - 1 month ago

$PMN Robinhood says up 25%

User Image Bigpun1973 Posted - 1 month ago

$PMN 🔥👍✅

User Image Stock_Titan Posted - 1 month ago

$PMN ProMIS Neurosciences to Present in Upcoming Investor Conferences in April https://www.stocktitan.net/news/PMN/pro-mis-neurosciences-to-present-in-upcoming-investor-conferences-in-z6wtc0dcabi6.html

User Image 7DAYSDIMENSIONS Posted - 1 month ago

$PMN It's going up just because Phase 1a is NOT interrupted, the more the time passes, the more we know that patients don't suffer ARIA. (head aches) Personnal opinion

User Image Stock_Titan Posted - 1 month ago

$PMN ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights https://www.stocktitan.net/news/PMN/pro-mis-neurosciences-announces-full-year-2023-financial-results-and-2vm72dhx9b3l.html

Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Farfel Gail M Chief Executive Offi.. Chief Executive Officer Dec 14 Buy 4.94 1,000 4,940 2,000 12/16/22
Kirwin Patrick D. Director Director Dec 13 Buy 4.69 3,000 14,070 27,998 12/15/22
Williams Eugene Director Director Dec 07 Buy 5.4864 1,000 5,486 156,930 12/08/22
Farfel Gail M Chief Executive Offi.. Chief Executive Officer Dec 06 Buy 5.7 1,000 5,700 1,000 12/08/22
Williams Eugene Director Director Dec 02 Buy 5.98 1,000 5,980 155,930 12/06/22
Williams Eugene Chairman and CEO Chairman and CEO Jul 11 Buy 9.80 1,000 9,800 154,930 07/12/22